• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
XVIVO
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
    • Info
    • Ownership structure
    • Insiders (PDMRs)
  • Press releases
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Financial reports – ESEF
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
    • Capital Markets Day
    • Earnings calls
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • Code of Conduct
  • Environmental Policy
  • Code of Conduct for Suppliers
  • Privacy policy
  • Contact us
  • Subscribe
  • Thank you
  • Error

Press releases 2022

  • All press releases
  • Regulatory Press Releases
2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
2022-12-30 10:00
News
IR
Swedish
Regulatory
LHFI
Corporate Action
Shares
Ökat antal aktier och röster i XVIVO Perfusion AB (publ)
2022-12-30 10:00
News
IR
English
Regulatory
LHFI
Corporate Action
Shares
Increased number of shares and votes in XVIVO Perfusion AB (publ)
2022-11-30 17:40
News
IR
Swedish
Regulatory
MAR
Corporate Information
Staff change
Christoffer Rosenblad utsedd till VD i XVIVO
2022-11-30 17:40
News
IR
English
Regulatory
MAR
Corporate Information
Staff change
Christoffer Rosenblad appointed as CEO of XVIVO
2022-11-30 11:10
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
M&A
XVIVO slutför förvärvet av maskin- och perfusionsverksamheten från Avionord S.r.l.
2022-11-30 11:10
News
IR
English
Regulatory
Listing Regulation
Corporate Action
M&A
XVIVO completes the acquisition of the machine and perfusion business from Avionord S.r.l.
2022-11-28 15:15
News
IR
English
Corporate Information
Staff change
XVIVO strengthens its executive management team by appointing Lena Hagman to Chief Operating Officer, COO
2022-11-28 15:15
News
IR
Swedish
Corporate Information
Staff change
XVIVO stärker sin ledningsgrupp genom att utse Lena Hagman till Chief Operating Officer, COO
2022-11-24 15:50
News
IR
Swedish
Corporate Information
Other Corporate Information
Positiva resultat presenterade från hjärtpreservationsstudien i Australien & Nya Zeeland
2022-11-24 15:50
News
IR
English
Corporate Information
Other Corporate Information
Positive results presented from the Australian & New Zealand heart preservation study
2022-10-27 07:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Delårsrapport januari – september 2022
2022-10-27 07:30
News
IR
English
Regulatory
MAR
Report
Interim
Q3
Interim Report January - September 2022
2022-10-21 11:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Telefonkonferens avseende delårsrapport
2022-10-21 11:30
News
IR
English
Corporate Information
Other Corporate Information
Conference call on Interim Report
2022-09-30 10:00
News
IR
English
Corporate Information
Other Corporate Information
Nomination committee of XVIVO Perfusion AB (publ)
2022-09-30 10:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Valberedning i XVIVO Perfusion AB (publ)
2022-09-27 08:55
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
XVIVO Perfusions vd Dag Andersson har avlidit
2022-09-27 08:55
News
IR
English
Regulatory
MAR
Corporate Information
Other Corporate Information
XVIVO Perfusion's CEO Dag Andersson has passed away
2022-09-21 07:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Presentation
XVIVO presenterar strategi för 2023-2027 på kapitalmarknadsdagen
2022-09-21 07:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Presentation
XVIVO presents strategy for 2023-2027 at its Capital Markets Day
2022-09-20 07:30
News
IR
Swedish
Corporate Information
Other Corporate Information
XVIVO har erhållit Breakthrough Device Designation från FDA för sin Liver Assist
2022-09-20 07:30
News
IR
English
Corporate Information
Other Corporate Information
XVIVO granted Breakthrough Device Designation from the FDA for the Liver Assist device
2022-08-24 15:00
News
IR
Swedish
Corporate Information
Presentation
XVIVOs kapitalmarknadsdag 2022
2022-08-24 15:00
News
IR
English
Corporate Information
Presentation
XVIVO Capital Markets Day 2022
2022-08-01 16:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
M&A
XVIVO ingår avtal om att förvärva sin italienska distributör - säkrar en unik affärsmodell
2022-08-01 16:15
News
IR
English
Regulatory
MAR
Corporate Action
M&A
XVIVO enters into an agreement to acquire its Italian distributor - securing a unique business model
2022-07-13 07:30
News
IR
English
Regulatory
MAR
VPML
Report
Interim
Q2
XVIVO presents interim report january-june 2022
2022-07-13 07:30
News
IR
Swedish
Regulatory
MAR
VPML
Report
Interim
Q2
XVIVO avlämnar delårsrapport januari-juni 2022
2022-06-30 07:30
News
IR
Swedish
Regulatory
LHFI
Corporate Action
Shares
Förändring av antalet aktier och röster i XVIVO Perfusion
2022-06-30 07:30
News
IR
English
Regulatory
LHFI
Corporate Action
Shares
Change in number of shares and votes in XVIVO Perfusion
2022-06-29 08:30
News
IR
English
Corporate Information
Other Corporate Information
Conference call on Interim Report
2022-06-29 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Telefonkonferens avseende delårsrapport
2022-05-19 15:00
News
IR
Swedish
Corporate Information
Other Corporate Information
CHU Toulouse i Frankrike introducerar program för maskinperfusion för lever och lunga med hjälp av XVIVOs teknologier
2022-05-19 15:00
News
IR
English
Corporate Information
Other Corporate Information
CHU Toulouse in France starts liver and lung perfusion programs using XVIVO technologies
2022-05-18 08:00
News
IR
Swedish
Corporate Information
Other Corporate Information
XVIVO tar viktiga steg i sin digitala transformationsresa i samarbete med världsledande Cleveland Clinic för att öka antalet framgångsrika lungtransplantationer
2022-05-18 08:00
News
IR
English
Corporate Information
Other Corporate Information
XVIVO to advance their digital transformation journey in partnership with the world-leading Cleveland Clinic to increase the number of successful lung transplants
2022-05-12 08:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Statlig ersättning för lung- och levertransplantation i Nederländerna - resultat från kliniska prövningar med XVIVOs ledande teknologier har spelat en viktig roll
2022-05-12 08:00
News
IR
English
Corporate Information
Other Corporate Information
Reimbursement established for lung and liver transplant in the Netherlands based on results from clinical trials with XVIVO's leading technologies
2022-05-04 08:00
News
IR
Swedish
Corporate Information
Other Corporate Information
XVIVO har tecknat avtal med ledande amerikanska sjukhus och levererat de första Kidney Assist Transport
2022-05-04 08:00
News
IR
English
Corporate Information
Other Corporate Information
XVIVO has executed agreements with leading US hospitals and delivered the first Kidney Assist Transport devices
2022-04-27 10:30
News
IR
English
Corporate Information
Other Corporate Information
XVIVO submits an IDE application to US FDA for its innovative heart technology – a significant milestone
2022-04-27 10:30
News
IR
Swedish
Corporate Information
Other Corporate Information
XVIVO lämnar in en IDE-ansökan till amerikanska FDA för sin innovativa hjärtteknologi – en betydande milstolpe
2022-04-26 16:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
General meeting
Report of the AGM
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
2022-04-26 16:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Report of the AGM
Kommuniké från årsstämma i XVIVO Perfusion AB (publ)
2022-04-25 07:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q1
XVIVO avlämnar delårsrapport januari-mars 2022
2022-04-25 07:30
News
IR
English
Regulatory
MAR
Report
Interim
Q1
XVIVO presents interim report January-March 2022
2022-04-13 08:30
News
IR
English
Corporate Information
Other Corporate Information
Conference call on Interim Report
2022-04-13 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Telefonkonferens avseende delårsrapport
2022-04-04 17:20
News
IR
English
Regulatory
VPML
Report
Annual
Annual report 2021
2022-04-04 17:20
News
IR
Swedish
Regulatory
VPML
Report
Annual
Årsredovisning 2021
2022-03-24 19:00
News
IR
English
Corporate Information
General meeting
Notice
Notice to attend the annual general meeting in XVIVO Perfusion AB (publ)
2022-03-24 19:00
News
IR
Swedish
Corporate Information
General meeting
Notice
Kallelse till årsstämma i XVIVO Perfusion AB (publ)
2022-03-23 17:45
News
IR
English
Regulatory
MAR
Corporate Information
Other Corporate Information
XVIVO obtains its first certificate under EU Medical Device Regulation (MDR) for Kidney Assist Transport
2022-03-23 17:45
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
XVIVO får sitt första certifikat enligt EUs förordning Medical Device Regulation (MDR) för Kidney Assist Transport
2022-02-02 13:00
News
IR
Swedish
Corporate Information
Other Corporate Information
XVIVO får viktigt marknadsgodkännande i Kina för PERFADEX® Plus – den globala standardbehandlingen för bevarande av lungor
2022-02-02 13:00
News
IR
English
Corporate Information
Other Corporate Information
XVIVO gains regulatory approval in China for PERFADEX® Plus – the global gold standard for lung preservation
2022-01-27 07:30
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
XVIVO presents Report on Operations 2021
2022-01-27 07:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
XVIVO avlämnar Bokslutskommuniké 2021
2022-01-21 22:50
News
IR
English
Regulatory
MAR
Corporate Information
Other Corporate Information
XVIVO’s Kidney Assist Transport receives 510(k) clearance by US FDA, which is XVIVO’s first regulatory cleared product for abdominal transplantation in the US
2022-01-21 22:50
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
XVIVOs Kidney Assist Transport får 510(k)-godkännande av amerikanska FDA och blir XVIVOs första regulatoriskt godkända produkt för transplantation av abdominala organ i USA
2022-01-12 10:15
News
IR
English
Corporate Information
Other Corporate Information
Conference call on Report on operations 2021
2022-01-12 10:15
News
IR
Swedish
Corporate Information
Other Corporate Information
Telefonkonferens avseende bokslutskommuniké 2021
2022-01-10 23:39
News
IR
Swedish
Correction
Corporate Information
Other Corporate Information
Rättelse: XVIVOs innovativa teknologi för bevarande av hjärtan har använts i världens första framgångsrika xenotransplantation (gris till människa)
2022-01-10 23:39
News
IR
English
Correction
Corporate Information
Other Corporate Information
Correction: XVIVO’s innovative preservation technology used in the world’s first ever successful heart xenotransplantation (pig to human)
2022-01-10 22:34
News
IR
Swedish
Corporate Information
Other Corporate Information
XVIVOs innovativa teknologi för bevarande av hjärtan har använts i världens första framgångsrika xenotransplantation (gris till människa)
2022-01-10 22:34
News
IR
English
Corporate Information
Other Corporate Information
XVIVO’s innovative preservation technology used in the world’s first ever successful heart xenotransplantation (pig to human)
2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
2022-12-30 10:00
News
IR
Swedish
Regulatory
LHFI
Corporate Action
Shares
Ökat antal aktier och röster i XVIVO Perfusion AB (publ)
2022-12-30 10:00
News
IR
English
Regulatory
LHFI
Corporate Action
Shares
Increased number of shares and votes in XVIVO Perfusion AB (publ)
2022-11-30 17:40
News
IR
Swedish
Regulatory
MAR
Corporate Information
Staff change
Christoffer Rosenblad utsedd till VD i XVIVO
2022-11-30 17:40
News
IR
English
Regulatory
MAR
Corporate Information
Staff change
Christoffer Rosenblad appointed as CEO of XVIVO
2022-11-30 11:10
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
M&A
XVIVO slutför förvärvet av maskin- och perfusionsverksamheten från Avionord S.r.l.
2022-11-30 11:10
News
IR
English
Regulatory
Listing Regulation
Corporate Action
M&A
XVIVO completes the acquisition of the machine and perfusion business from Avionord S.r.l.
2022-10-27 07:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Delårsrapport januari – september 2022
2022-10-27 07:30
News
IR
English
Regulatory
MAR
Report
Interim
Q3
Interim Report January - September 2022
2022-09-27 08:55
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
XVIVO Perfusions vd Dag Andersson har avlidit
2022-09-27 08:55
News
IR
English
Regulatory
MAR
Corporate Information
Other Corporate Information
XVIVO Perfusion's CEO Dag Andersson has passed away
2022-09-21 07:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Presentation
XVIVO presenterar strategi för 2023-2027 på kapitalmarknadsdagen
2022-09-21 07:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Presentation
XVIVO presents strategy for 2023-2027 at its Capital Markets Day
2022-08-01 16:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
M&A
XVIVO ingår avtal om att förvärva sin italienska distributör - säkrar en unik affärsmodell
2022-08-01 16:15
News
IR
English
Regulatory
MAR
Corporate Action
M&A
XVIVO enters into an agreement to acquire its Italian distributor - securing a unique business model
2022-07-13 07:30
News
IR
English
Regulatory
MAR
VPML
Report
Interim
Q2
XVIVO presents interim report january-june 2022
2022-07-13 07:30
News
IR
Swedish
Regulatory
MAR
VPML
Report
Interim
Q2
XVIVO avlämnar delårsrapport januari-juni 2022
2022-06-30 07:30
News
IR
Swedish
Regulatory
LHFI
Corporate Action
Shares
Förändring av antalet aktier och röster i XVIVO Perfusion
2022-06-30 07:30
News
IR
English
Regulatory
LHFI
Corporate Action
Shares
Change in number of shares and votes in XVIVO Perfusion
2022-04-26 16:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
General meeting
Report of the AGM
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
2022-04-26 16:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Report of the AGM
Kommuniké från årsstämma i XVIVO Perfusion AB (publ)
Next
About us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on three continents. The company is listed on Nasdaq.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivogroup.com

 

Report a violations or breach here: Whistleblower

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2023 XVIVO. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO. Read more about Cookies

Approve